Product Name | YM-01 |
Description |
Hsp70 Inhibitor |
Purity | >98% (HPLC) |
CAS No. | 409086-68-6 |
Molecular Formula | C20H20ClN3OS2 |
Molecular Weight | 417.97 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in warm water (2 mg/ml) |
Source | Synthetic |
Appearance | Orange red solid |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
Cite This Product | YM-01 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-121) |
Alternative Names | 2-((Z)-((E)-3-ethyl-5-(3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-1-methylpyridin-1-ium chloride; YM-1 |
Research Areas | Alzheimer's Disease, Apoptosis, Cancer, Cell Signaling, Heat Shock, Neurodegeneration, Neuroscience |
Scientific Background | YM-01 is an allosteric inhibitor of Hsp70 that binds within its nucleotide-binding domain, adjacent to the ATP/ADP pocket. It disrupts Hsc70-Bag1 interactions and enhances Hsp70 binding to misfolded proteins. In neuroscience, YM-01 has shown efficacy in reducing tau protein levels in cellular and animal models of tauopathy, including Alzheimer's disease. It restores long-term potentiation in brain slices from tau-overexpressing mice, indicating potential for cognitive recovery. YM-01’s dual activity in protein quality control and synaptic function makes it a valuable tool for studying and potentially treating tau-related neurodegenerative disorders. |
References |
1. Wang et al., 2013 Nature Chem. Biol. 9: 112-118. 2. Abisambra et al., 2013 Biol. Psychiatry, 74: 367-374. 3. Koren et al. PLoS One 7:e35566. 4. Morishima et al. 2011 Biochemistry. 50: 7146. 5. Davis et al. 2012 J. Immunol. 189: 4488. |
Reviews
There are no reviews yet.